Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2006-06-27
2006-06-27
Li, Q. Janice (Department: 1632)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S093100, C424S093200, C435S325000, C435S346000, C435S455000, C435S320100, C435S373000
Reexamination Certificate
active
07067120
ABSTRACT:
The present invention provides an antigen-presenting cell(APC)/tumor cell conjugate, wherein the antigen-presenting cell (APC) is modified by a cytokine gene selected from the group consisting of IL-2, IL-3, IL-4, IL-6, IL-12, IL-18, IFNα, IFNβ, IFNγ, TNF, TGF, GM-CSE, and the combination thereof. The conjugate is useful as a tumor vaccine to significantly induce an immunity specifically against the tumor cell The present invention also provides the method for preparing the conjugate and a pharmaceutical composition containing said conjugate.
REFERENCES:
patent: 2002/0168351 (2002-11-01), Ohno
Virgule: Dictionary.com
Nishioka et al, Cancer Res 1999;59:4035-41.
Osaki et al, Gene Ther 1999;6:808-15.
Tanaka et al, Cancer Res. 2000;60:4838-44.
“IFN-γ-Dependent and -Independent Mechanisms in Adverse Effects Caused by Concomitant Administration of IL-18 and IL-12”, by Nakamura et al. The Journal of Immunology. 2000. 164: 3330-3336.
“Interleukin-12 and Interleukin-18 Synergistically Induce Murine Tumor Regression Which Involves Inhibition of Angiogenesis”, by Coughlin et al. The American Society for Clinical Investigation. Inc., Antitumor Response of IL-12 and IL-18. vol. 101. No. 6. Mar. 1998. 1441-1452.
“Use of Peptide Libraries to Map the Substrate Specificity of a Peptide-Modifying Enzyme: A 13 Residue Consensus Peptide Specifies Biotinylation inEscherichia coli”, by Peter J. Schatz. Bio/Technology vol. 11 Oct. 1993: 1138-1143.
“Phenotypic Analysis of Antigen-Specific T Lymphocytes”, by Altman et al. Science. vol. 274. Oct. 4, 1996. pp. 94-96.
“Identification of Tyrosinase-related Protein 2 as a Tumor Rejection Antigen for the B16 Melanoma”, by Bloom et al. The Journal of Experimental Medicine. vol. 185. No. 3. Feb. 3, 1997; 453-459.
“In VivoGene Therapy for α -Fetoprotein-producing Hepatocellular Carcinoma by Adenovirus-mediated Transfer of Cytosine Deaminase Gene”, by Kanai et al. Cancer Research 57.461-465. Feb. 1, 1997.
“Dendritic Cells Retrovirally Transduced with a Model Antigen Gene Are Therapeutically Effective against Established Pulmonary Metastases”, by Specht et al. The Journal of Experimental Medicine. vol. 186. No. 8. Oct. 20, 1997. 1213-1221.
“Cutting Edge: Physical Interaction Between Dendritic Cells and Tumor Cells Results in an Immunogen That Induces Protective and Therpeutic Tumor Rejection”, by Celluzzi et al. The Journal of Immunology. vol. 18. 1998. pp. 3081-3085.
“Improved detection of nitric oxide radical (NO) production in an activated macrophage culture with a radical scavenger, carboxy PTIO, and Griess reagent”, by F. Amano et al. FEBS Letters 368 (1995) 425-428.
“Induction of Rapid T Cell Activation and Tolerance by Systemic Presentation of an Orally Administered Antigen”, by Gütgemann et al. Immunity. vol. 8. 667-673. Jun. 1998.
“Frequency of Class I HLA-Restricted Anti-HIV CD8+ T Cells in Individuals Receiving Highly Active Antiretroviral Therapy (HAART)”, by Gray et al. The Journal of Immunology. vol. 21. 1999. pp. 1780-1788.
“Recombinant modified vaccinia virus Ankara-simian immunodeficiency virus gag pol elicits cytotoxic T lymphcytes in rhesus monkeys detected by a major histocompatibility complex class I/peptide tetramer”, by Seth et al. Proc. Natl. Acad. Sci. USA. vol. 95. pp. 10112-10116. Aug. 1998. Medical Sciences.
“Isolation of High Avidity Melanoma-Reactive CTL from Heterogeneous Populations Using Peptide MHC Tetramers”, by Yee et al. The Journal of Immunology. vol. 23. 1999. pp. 2227-2234.
“The α2Domain of H-2D4Restricts the Allelic Specificity of the Murine NK Cell Inhibitory Receptor Ly-49A”, by Sundbäck et al. The Journal of Immunology. vol. 24. 1998. pp. 5971-5978.
T Helper Cell Type 1-associated and Cytotoxic T Lymphocyte-mediated Tumor Immunity Is Impaired in Interleukin 4-deficient mice, by Schuler et al. The Journal of Experimental Medicine. vol. 189. No. 5. Mar. 1, 1999: 803-810.
Interleukin 18 Transfection Enhances Antitumor Immunity Induced by Dendrtic Cell-Tumor Cell Conjugates, by Ju et al. Cancer Research 61. 3735-3740. May 1, 2001.
“Therapeutic Vaccination for Cancer”, by Drew M. Pardoll. Clinical Immunology, vol. 95. No. 1. Apr. pp. S44-S62, 2000.
“Abrogation of Tumorigenicity and Metastasis of Murine and Human Tumor Cells by Transfection with the Murine IFN-β Gene: Possible Role of Nitric Oxide”, by Xie et al. Clinical Cancer Research, vol. 3 2283-2294. Dec. 1997.
“Dendritic Cells in Cancer Immunotherapy”, by Fong et al. Annual Reviews, 2000 pp. 245-273.
“Murine dendritic cells pulsedin vitrowith tumor antigen induce tumor resistancein vivo”, by Flamand et al. Dendritic cells in immunotherapy. Eur. J. Immunol. 1994. 24:605-610.
“Peptide-pulsed Dendritic Cells Induce Antigen-specific, CTL-mediated Protective Tumor Immunity”, by Celluzzi et al. J. Exp. Med., The Rockefeller University Press, vol. 183 Jan. 1996 283287.
“Murine dendritic cells-pulsed with whole tumor lysates mediate potent antitumor immune responsesin vitroandin vivo”, by Fields et al. Proc. Natl. Acad. Sci. USA. vol. 95. pp. 9482-9487. Aug. 1998, Immunology.
“Induction of Tumor Immunity and Cytotoxic T Lymphocyte Responses Using Dendritic Transfected with Messenger RNA Amplified from Tumor Cells”, by Boczkowski et al. Cancer Research 60. 10284034. Feb. 15, 2000.
“In vivo antitumor effects of murine interferon-γ-inducing factor interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites”, by Mieallef et al. Cancer Immunol Immunother (1997)43: 361-367.
“IFN-γ-Inducing Factor II -18 Administration Mediates IFN-γ-and IL-12-Independent Antitumor Effects”, by Osaki et al. The Journal of Immunology. 1998. 160: 1742-1749.
Dianwen Ju
Tao Qun
Ye Dan
Li Q. Janice
Merchant & Gould P.C.
Shanghai Medipharm Biotech Co., Ltd.
LandOfFree
Cytokine gene modified antigen-presenting cell/tumor cell... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cytokine gene modified antigen-presenting cell/tumor cell..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cytokine gene modified antigen-presenting cell/tumor cell... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3652847